MyLungCancerTeam

It sounds like you are undergoing a combination treatment plan for lung cancer. While the specific combination of Carboplatin, Alimta (Pemetrexed), and Osimertinib (Tagrisso) isn't detailed in the knowledge base, here is some information about Osimertinib (Tagrisso):

- Tagrisso (Osimertinib)
- Usage: Approved by the FDA Show Full Answer

It sounds like you are undergoing a combination treatment plan for lung cancer. While the specific combination of Carboplatin, Alimta (Pemetrexed), and Osimertinib (Tagrisso) isn't detailed in the knowledge base, here is some information about Osimertinib (Tagrisso):

- Tagrisso (Osimertinib):
- Usage: Approved by the FDA to treat adults with non-small-cell lung cancer (NSCLC) whose tumors are positive for specific EGFR mutations.
- Mechanism: It works by binding to specific mutant kinases on cancer cells, preventing them from receiving growth factors needed for replication, thus slowing tumor growth.
- Administration: Taken orally as a tablet once daily.
- Common Side Effects: Vision problems, nausea, diarrhea, vomiting, edema, constipation, abnormal liver function tests, fatigue, decreased appetite, upper respiratory infection, dizziness, and nerve problems.
- Serious Side Effects: Liver damage, vision loss, abnormal heart rhythms, fetal harm, and interstitial lung disease.

For more detailed information about your treatment plan, it's best to consult with your healthcare provider.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Tagrisso (Osimertinib) for Lung Cancer | MyLungCancerTeam

Xalkori (Crizotinib) for Lung Cancer | MyLungCancerTeam